Published: 2020-05-21

Effect of sodium-glucose transport protein 2 inhibitors on serum uric acid: an outpatient based prospective interventional study

Dipan Saha, Subhayan Das, Ramnarayan Maiti, Swarnali Paul


Background: Hyperuricemia is considered to be associated with increased risk of cardiovascular diseases. It has been found to be related to features of metabolic syndromes like hyperglycemia and dyslipidemia. Sodium-glucose transport protein 2 (SGLT2) inhibitors are known to have a decremental effect on serum uric acid level. We evaluated the effect of SGLT2 inhibitors on serum uric acid of diabetic population.

Methods: In this prospective study we recruited 50 type 2 diabetes mellitus (T2DM) patients who were on metformin monotherapy and were having inadequate glycemic control. Patients were prescribed SGLT2 inhibitors as an add-on therapy. Serum uric acid of the subjects was measured at the baseline and after 3 months. The primary outcome was to observe changes in serum uric acid (SUA) levels from the baseline to the end of the study. Glycemic changes were determined by observing the changes in glycated haemoglobin (HbA1c) levels (if any).

Results: The study population was predominantly male (82%). BMI wise most of the subjects (44%) were overweight. Mean HbA1c of total population was 7.65±0.5, whereas mean serum uric acid was 6.31±0.72 at the baseline. After 3 months HbA1C and serum uric acid levels were 7.45±0.50 and 6.06±0.64 respectively. Both the changes were statistically significant (p<0.005).

Conclusions: SGLT2 inhibitors could improve glycemic control and lower SUA levels in patients with uncontrolled T2DM. Randomized study with bigger sample size and longer study period are required to further demonstrate the effect of SGLT2 inhibitors on serum uric acid and explore the potential underlying mechanisms.


SGLT, Uric acid, Diabetes

Full Text:



Hsia DS, Grove O, Cefalu WT. An Update on Sodium-Glucose Co-transporter-2 Inhibitors for the Treatment of Diabetes Mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73-9.

Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. 2014;16:457-66.

Desouza CV, Gupta N, Patel A. Cardiometabolic Effects of a New Class of Antidiabetic Agents. Clinical Therapeutics. 2015;1:1-17.

Liying C, Wenhua Z, Zhouwen C, Honglei D, Jing R, Jianhua C, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-8.

Wang H, Zhang H, Sun L, Guo W. Am J Transl Res. 2018;10(9):2749-63.

Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21:1291-8.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo controlled trial. Lancet. 2010;375:2223-33.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients with Type 2 Diabetes Mellitu. Clin Pharmacol Ther. 2009;85(5):513-9.

Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(4):426-9.

Hao Z, Xiao H, Shao H, Tian F. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial. Therapeutics Clin Risk Management. 2018;14:2407-13.

Zhao D, Liu H, Dong P. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Human Hypertension. 2018;33(4):327-39.

Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology Metab Syndrome. 2013;5 (1):6.

Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458-62.